Industry Annoyed Over Delay In Renewal Of Import Registration Licences
By DCGI Office
The drug importers in
the country are annoyed over what they termed as 'the avoidable delay'
in the process of renewal of import registration licences by the
office of the Drug Controller General of India (DCGI). The entire
process which should not normally take more than two or three months
now takes more than a year, for reasons best known to the authorities
According to sources in
the industry, there is a lot of delay in renewing the import
registration by the DCGI office, adversely affecting the business...
Medical Device Cos Want Export Council
The domestic medical
devices industry has mooted the formation of a medical export council
on the lines of Pharmexcil (Pharma Export Council), a body under the
commerce ministry that represents the interest of pharma exporters...
State DCs To Collect Data On Impact Of Revised Sch M Norms On SSIs
The Drugs Controller
General (India) has asked all State drug controllers to collect the
information on the closure of small scale pharma units following the
amendment of the Drugs and Cosmetics Act enforcing the revised
Schedule M guidelines in the country from July, 2005...
Suggests Public Private Model For Development, Maintenance Of New
The Department of
Pharmaceuticals (DoP) which took the initiative of the project of
establishing six new National Institutes of Pharmaceutical Education
and Research (NIPERs) has suggested in its detailed project report
that development and maintenance of infrastructural facilities should
be under the Public Private Partnership (PPP) model...
Johnson & Johnson Net Up By 29.1% To US$ 4.5 Billion In Q1
Johnson & Johnson (J&J)
has posted strong growth in net profit during the first quarter ended
March 2010. Its net profit went up by 29.1 per cent to US$ 4,526
million from US$ 3,507 million in the similar period of last year. Its
sales increased by 4 per cent to US$ 15,631 million from US$ 15,026
For New Growth Avenues In Emerging Markets, And India
The company, having established its plant
in 1995 in India is looking for new growth avenues in emerging
markets, and India. Its first office in the country was set up in
1995. BDís India revenues, which topped $100 million in the past year,
come from selling syringes, diagnostic kits, lab equipment and related
gear used in healthcare. As growth prospects get bleaker at home, the
company is looking for new growth avenues in emerging markets, and
India, with its Rs. 5,750 Crore medical technology market looks
attractive. Now the $7.1-billion giant wants to ramp up its
development and manufacturing operations in India ó it is shifting
production from Sweden to India.
Researchers Make Artificial Blood Vessels From Jatropha Bhavnagarís
CSMCRI Develops Biodegradable Polymer
ARTIFICIAL blood vessels from jatropha?
After bio-diesel, this humble tropical weed could now help Indian
researchers to indigenously develop blood vessels.
Explore Global Medical Devices Market With Rs 100cr Investment
The New Delhi based PolyMedicure Pvt.
Ltd., manufacturer and supplier of medical devices and disposables, is
planning to invest Rs. 100 crore by 2013 to expand its presence in
overseas market with a thrust on safety medical devices and
outsourcing manufacturing and research activities.
Healthcare To Grow Medical Devices Biz, Enters Orthopaedic Implants
Market With US Tie-up
TTK Healthcare, a part of Rs 1500 crore
TTK group and producing heart valves, has forayed into the orthopaedic
implants segment dominated by players like Johnson & Johnson, Zimmer,
Stryker and Indus.